<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4782">
  <stage>Registered</stage>
  <submitdate>24/05/2012</submitdate>
  <approvaldate>24/05/2012</approvaldate>
  <nctid>NCT01609296</nctid>
  <trial_identification>
    <studytitle>IN.PACT Global Clinical Study</studytitle>
    <scientifictitle>The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral Drug-Eluting Balloon.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>10048613</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - IN.PACT Admiral Drug Eluting Balloon

Experimental: IN.PACT Admiral DEB - The subjects in this trial will be treated with the IN.PACT Admiral percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as "IN.PACT Admiral DEB")manufactured by Medtronic. The IN.PACT Admiral is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial.


Treatment: devices: IN.PACT Admiral Drug Eluting Balloon
IN.PACT Admiral percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Endpoint Clinical Cohort - Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as:  Any re-intervention within the target lesion(s) due to symptoms or drop of ABI = 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Endpoint Imaging Cohort - Primary Patency within 12 months post-index procedure, which is defined as: Freedom from clinically-driven TLR and  Freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) = 2.4 Restenosis determined by either PSVR &gt;2.4 as assessed by an independent DUS core lab or &gt;50% stenosis as assessed by an independent angiographic core lab</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 12 months post-index procedure.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>MAEs - MAE (Major Adverse Events)is defined as all-cause mortality, clinically-driven TVR (Target Vessel Revascularization), major target limb amputation, thrombosis at the target lesion site.</outcome>
      <timepoint>30 days, 6, 12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>at 30 days, 6, 12, 24, 36, 48 and 60 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-driven TLR</outcome>
      <timepoint>at 30 days, 6, 24, 36, 48 and 60 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-driven TVR - Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of = 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</outcome>
      <timepoint>at 30 days, 6, 12, 24, 36, 48 and 60 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TLR</outcome>
      <timepoint>at 6, 12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TVR</outcome>
      <timepoint>at 6, 12, 24, 36, 48 and 60 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major target limb amputation</outcome>
      <timepoint>at 30 days, 6, 12, 24, 36, 48 and 60 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first clinically-driven TLR</outcome>
      <timepoint>through 60 months post-index procedure.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to all-cause mortality</outcome>
      <timepoint>through 60 months post-index procedure.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary sustained clinical improvement - Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</outcome>
      <timepoint>at 6, 12, 24, 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary sustained clinical improvement - Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</outcome>
      <timepoint>at 6, 12, 24, 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immediate hemodynamic improvement - Immediate hemodynamic improvement is defined as an ABI improvement of = 0.1 or to an ABI = 0.9.</outcome>
      <timepoint>at post-index procedure.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sustained hemodynamic improvement - Sustained hemodynamic improvement is defined as persistent improvement of ABI-values with = 0.1 as compared to baseline values or to an ABI = 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</outcome>
      <timepoint>at 6, 12, 24, 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Walking impairment evaluation by Walking Impairment Questionnaire (WIQ)</outcome>
      <timepoint>at 6, 12, 24, 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Walking distance as measured by 6 Minute Walk Test</outcome>
      <timepoint>at 6, 12, 24, 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health related Quality of life scores (EQ5D)</outcome>
      <timepoint>at 6, 12, 24, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device success - Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</outcome>
      <timepoint>Index-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical success - Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</outcome>
      <timepoint>prior to discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Imaging cohort: Duplex-defined binary restenosis (PSVR &gt; 2.0) of the target lesion</outcome>
      <timepoint>at 12 months, or at the time of re-intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Imaging cohort: 21. Duplex-defined binary restenosis (PSVR &gt; 3.4) of the target lesion</outcome>
      <timepoint>at 12 months, or at the time of re-intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>General inclusion Criteria:

          -  Age = 18 years or minimum age as required by local regulations.

          -  Subject with documented diagnosis of peripheral arterial disease (PAD) in the
             superficial femoral artery (SFA) and/or popliteal artery (PA) (including P1, P2, P3)
             classified as Rutherford class 2-3-4.

          -  Angiographically documented single or multiple lesions/occlusions (de novo or
             re-stenotic lesion(s) or in-stent restenosis) within the target vessels with a minimum
             lesion length of 2 cm including bilateral disease if both limbs are treated within 35
             days.

        General exclusion Criteria:

          -  High probability of non-adherence to Clinical Investigation Protocol follow-up
             requirements.

          -  Failure to successfully cross the target lesion with a guide wire (successful crossing
             means tip of the guide wire distal to the target lesion in the absence of flow
             limiting dissections or perforations).

          -  Lesion within or adjacent to an aneurysm or presence of a popliteal aneurysm.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1535</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>NSW 2050 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Bueos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Gratz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Mödling</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Dendermonde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Tienen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sherbrooke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Neiva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rosenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tübingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemét</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>'s Hertogenbosch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecinie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banská Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Maribor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Solna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Fribourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Luzern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Endovascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiral Drug
      Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral
      and/or popliteal arteries in a "real world" patient population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01609296</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gunnar Tepe, MD</name>
      <address>Klinikum Rosenheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>